Clinical Trial
Published on 09 Mar 2026
Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma
in Cancer Immunity and Immunotherapy
- 114 views
Clinical Trial
Published on 09 Mar 2026
in Cancer Immunity and Immunotherapy
Original Research
Published on 09 Mar 2026
in Anxiety and Stress Disorders
Original Research
Published on 09 Mar 2026
in Aging and Dental Medicine
Original Research
Published on 09 Mar 2026
in Terrestrial Microbiology
Original Research
Published on 09 Mar 2026
in Auditory Cognitive Neuroscience
Review
Published on 09 Mar 2026
in Pharmacology of Infectious Diseases
Original Research
Published on 09 Mar 2026
in Mechatronics
Editorial
Published on 09 Mar 2026
in Ethical Digital Health
Original Research
Published on 09 Mar 2026
in Inflammation
Original Research
Published on 09 Mar 2026
in Educational Psychology
Addendum
Published on 09 Mar 2026
in Occupational Health and Safety
Original Research
Published on 09 Mar 2026
in Geohazards and Georisks
Systematic Review
Published on 09 Mar 2026
in Machine Learning and Artificial Intelligence
Correction
Published on 09 Mar 2026
in Health Informatics
Original Research
Published on 09 Mar 2026
in Computational Genomics
Systematic Review
Published on 09 Mar 2026
in Environmental Health and Exposome